抗核抗体检测变异性对系统性红斑狼疮临床试验入组资格评估的影响
本研究使用5种市售免疫荧光法(IFA)试剂盒,评估181例参加抗白介素-6抗体II期临床试验的系统性红斑狼疮患者的抗核抗体(ANA)状态。中心实验室判定ANA阴性率为23.8%,而各试剂盒阴性率从0.6%到27.6%不等,提示IFA试剂盒性能差异可影响试验资格判定。
要点
- 中心实验室判定ANA阴性率为23.8%,但不同IFA试剂盒阴性率差异大(0.6%–27.6%)。
- 两种IFA试剂盒显示较高ANA阴性率,且阳性与阴性样本在抗dsDNA、C3及干扰素表达上存在差异。
- IFA试剂盒性能差异可能影响临床试验入组资格及对试验药物的反应性评估。
核心结论
- IFA试剂盒性能差异可导致ANA阴性率显著不同,从而影响系统性红斑狼疮临床试验的入组资格判定。
- 当试剂盒产生较高ANA阴性率时,ANA状态可能与其它血清学指标及干扰素特征相关,潜在影响对试验药物的反应性。
研究设计与样本
- 使用5种市售IFA试剂盒评估181例参加抗白介素-6抗体II期临床试验的系统性红斑狼疮患者的ANA状态。
- 入组时详细回顾医疗记录以核实历史ANA值,并将IFA结果与入组时临床及血清学特征关联。
主要发现
- 中心实验室判定ANA阴性率为23.8%(181例患者中)。
- 评估的IFA试剂盒显示ANA阴性率从0.6%到27.6%不等。
- 两种IFA试剂盒显示显著频率的ANA阴性,且阳性与阴性样本在抗双链DNA水平、C3水平、其他ANA存在及高干扰素表达频率上存在差异。
关键数值与推荐
- ANA阳性是系统性红斑狼疮新疗法试验的入组标准之一。
- 中心实验室判定ANA阴性率为23.8%,各IFA试剂盒阴性率范围为0.6%至27.6%。
临床怎么用
- 在筛选患者入组系统性红斑狼疮临床试验时,需注意IFA试剂盒性能差异对ANA状态判定的影响。
- ANA状态应结合其他血清学指标(如抗dsDNA、C3)及干扰素特征综合评估,而非仅依赖单一IFA结果。
局限性
- 本研究基于181例参加特定II期临床试验的患者,结果可能不适用于其他人群或试验设置。
- 仅评估了5种市售IFA试剂盒,未涵盖所有可用检测方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the development of novel therapies for systemic lupus erythematosus, antinuclear antibody (ANA) positivity represents a criterion for trial eligibility. Since as many as 30% of patients enrolled in trials have been ANA negative, we evaluated the performance characteristics of immunofluorescence assays (IFAs) for ANA determinations for screening. METHODS: This study used 5 commercially available IFAs to assess the ANA status of 181 patients enrolled in a phase II clinical trial for an anti-interleukin-6 antibody. Enrollment included a detailed review of medical records to verify a historical ANA value. IFA results were related to various clinical and serologic features at enrollment. RESULTS: While the frequency of ANA negativity assessed by the central laboratory was 23.8% in a cohort of 181 patients, the evaluated IFA kits demonstrated frequencies of negativity from 0.6 to 27.6%. With 2 IFA kits showing a significant frequency of ANA negativity, positive and negative samples differed in levels of anti-double-stranded DNA, C3, and presence of other ANAs as well as the frequency of high interferon (IFN) expression. CONCLUSION: These findings indicate that, when used for screening, IFAs can vary because of performance characteristics of kits and thus can affect determination of trial eligibility. With kits producing a significant frequency of ANA negativity, ANA status can be associated with other serologic measures as well as the presence of the IFN signature, potentially affecting responsiveness to a trial agent.
引用
- Pisetsky DS, Thompson DK, Wajdula J, et al. Variability in Antinuclear Antibody Testing to Assess Patient Eligibility for Clinical Trials of Novel Treatments for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019. PMID: 31385442. doi:10.1002/art.40910
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。